The investigation into dementia is undergoing a turning point, according to the World Alzheimer Report 2026, released by Alzheimer’s Disease International (ADI). This report details a new phase in clinical studies concerning Alzheimer's disease and other forms of dementia.
According to the document, Alzheimer's disease should no longer be considered universally untreatable. In the last five years, new drugs have demonstrated the ability to slightly slow the progression of the illness in early stages. Furthermore, growing evidence suggests that certain forms of dementia can be delayed or even prevented by reducing risk factors.
The scientific landscape is also characterized by increased activity. Currently, hundreds of global clinical trials are underway, seeking new medications, diagnostic methods, and lifestyle interventions aimed at identifying, treating, or slowing cognitive decline.
Comparison with Oncology
ADI draws a parallel between the current state of dementia research and what occurred in oncology during the 1990s. At that time, although the first cancer treatments were incomplete, they paved the way for precision medicine, drug combinations, and earlier interventions.
However, the report emphasizes that there is still no discovery for Alzheimer's comparable to penicillin or statins. The transformation is occurring more gradually, shifting from a focus on immediate cure to strategies for prevention, management, and risk mitigation.
The number of candidate substances under investigation for dementia has grown by approximately 40% in the last decade. Currently, researchers are evaluating 158 potential therapies in 192 clinical trials worldwide. Results from eight Phase 3 trials are expected only in 2026, a phase that tests treatments in a large volume of participants and compares them with standard care.
It is relevant to note that more than a third of the dementia drugs in development were initially created to treat other pathologies. Scientific progress is not limited to medications; the report highlights that reducing risk factors plays a crucial role in preventing or delaying cases of dementia.
Based on the evidence presented, it is estimated that up to 45% of cases could be prevented or postponed by adopting an approach that modifies 14 risk factors throughout life. These factors include hypertension, depression, sedentary lifestyle, smoking, diabetes, excessive alcohol consumption, and high cholesterol levels.
The potential impact of this strategy gains great relevance given the aging of the world population. Estimates cited by ScienceAlert project that 139 million people will live with dementia in 2050. Even small delays in the onset of cognitive decline could result in millions fewer cases.
Challenges in Access and Diagnosis
Despite notable advances, access to new treatments remains a significant obstacle. One of the main challenges highlighted by the report is the difficulty in identifying patients in the early stages of the disease, the moment when certain emerging therapies can be applied.
Neuroradiologist Emer MacSweeney observes that many people who are likely already in the early stages of Alzheimer's end up undetected. She warns: 'The biggest mistake happening right now is that people who clearly, obviously, probably are in the early stages of Alzheimer's are being ignored and completely overlooked... because this window of opportunity for treatment is truly small.'
According to MacSweeney, patients often do not receive adequate information about clinical trials or how to gain access to new medications. She argues: 'We need a change in mindset in the medical profession to ensure that more people are informed about clinical trials and receive support to participate in them. We need action, not rhetoric.'
Diagnosis constitutes another major hurdle. In the United Kingdom, for example, only about 2% of individuals diagnosed with Alzheimer's have access to the gold-standard diagnostic test, according to a study conducted by Jonathan Schott, Medical Director of Alzheimer’s Research UK.
Blood tests capable of detecting biomarkers linked to dementia are emerging as a promising solution. Although these tools have shown positive results in preliminary studies, they still require population-scale evaluation to confirm their ability to accurately identify people with early signs of cognitive decline.
The report concludes that 'the future of dementia treatment may depend as much on family doctors in Havana, Lima, or Bangalore as on billion-dollar laboratories in California.' The World Alzheimer Report 2026, titled 'A New Era in Dementia Clinical Trials,' analyzes this new moment in research, covering everything from volunteer recruitment and retention to ethical, safety, regulatory, global representation, and inclusion issues in studies.
Historically, between 2000 and 2020, over 99% of experimental drugs for dementia failed in clinical trials. The current scenario, however, signals a significant shift in this history. Although a cure remains distant, the report considers it to be more plausible than in any other period. The challenge for the next decade will be to transform participation in dementia research from an act dependent on luck or persistence into a real possibility for anyone interested.